EP1014977A4 - Diagnose von migraine begleitet von aura, depression und angst durch allelvariationen in dopaminergen genen - Google Patents

Diagnose von migraine begleitet von aura, depression und angst durch allelvariationen in dopaminergen genen

Info

Publication number
EP1014977A4
EP1014977A4 EP97938536A EP97938536A EP1014977A4 EP 1014977 A4 EP1014977 A4 EP 1014977A4 EP 97938536 A EP97938536 A EP 97938536A EP 97938536 A EP97938536 A EP 97938536A EP 1014977 A4 EP1014977 A4 EP 1014977A4
Authority
EP
European Patent Office
Prior art keywords
aura
migraine
anxiety
depression
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97938536A
Other languages
English (en)
French (fr)
Other versions
EP1014977A1 (de
Inventor
Stephen J Peroutka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1014977A4 publication Critical patent/EP1014977A4/de
Publication of EP1014977A1 publication Critical patent/EP1014977A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP97938536A 1996-08-22 1997-08-21 Diagnose von migraine begleitet von aura, depression und angst durch allelvariationen in dopaminergen genen Withdrawn EP1014977A1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2439996P 1996-08-22 1996-08-22
US3609197P 1997-01-17 1997-01-17
US36091P 1997-01-17
PCT/US1997/014830 WO1998007426A1 (en) 1996-08-22 1997-08-21 Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes

Publications (2)

Publication Number Publication Date
EP1014977A4 true EP1014977A4 (de) 2000-07-05
EP1014977A1 EP1014977A1 (de) 2000-07-05

Family

ID=26698401

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97938536A Withdrawn EP1014977A1 (de) 1996-08-22 1997-08-21 Diagnose von migraine begleitet von aura, depression und angst durch allelvariationen in dopaminergen genen

Country Status (5)

Country Link
EP (1) EP1014977A1 (de)
JP (1) JP2001527520A (de)
AU (1) AU737893B2 (de)
CA (1) CA2263149A1 (de)
WO (1) WO1998007426A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1154736E (pt) * 1999-02-22 2005-02-28 Univ Miami Valvula mini-capsulorrexe
US20010053849A1 (en) * 1999-06-16 2001-12-20 Mary Jeanne Kreek Plural biological sample arrays, and preparation and uses thereof
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550021A (en) * 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PEROUTKA S.J.: "Dopamine and migraine", NEUROLOGY, vol. 4, no. 3, September 1997 (1997-09-01), pages 650 - 656, XP002118937 *
See also references of WO9807426A1 *

Also Published As

Publication number Publication date
WO1998007426A1 (en) 1998-02-26
CA2263149A1 (en) 1998-02-26
AU737893B2 (en) 2001-09-06
JP2001527520A (ja) 2001-12-25
EP1014977A1 (de) 2000-07-05
AU4083797A (en) 1998-03-06

Similar Documents

Publication Publication Date Title
CA2195093A1 (en) Use of droloxifene for the treatment of prostatic diseases, endometriosis and obesity
ZA9711119B (en) Compatibilized silica and polymer silica-reinforced master-batch containing same.
NZ329239A (en) Compositions comprising an organic polymer and an alkoxysilane, use in waterproofing compositions
ATE224931T1 (de) Russzusammensetzungen und verbesserte polymerzusammensetzungen
HUP0004484A3 (en) Desaturase genes and their use
HUP0104392A3 (en) Acquired resistance npr genes and uses thereof
EP0924983A4 (de) S(-)-tolterodin in der behandlung urinärer und gastrointestinaler störungen
AU7528001A (en) The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
SI0984960T1 (en) N-triazolyl-2-indolecarboxamides and their use as cck-a agonists
ZA200200294B (en) Corticotropin releasing factor receptor 2 deficient mice and uses thereof.
IL127468A0 (en) Substituted benzylidene formamides acetamides and propionamides
DE69738157D1 (de) Polymorphismus und neue gene in der region des menschlichen hemochromatosisgens
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
AU4083797A (en) Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes
ZA9711456B (en) VEGF-B/receptor complex and uses thereof.
NZ513739A (en) Cloning of cDNA of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer
EP1007675A4 (de) Mhc klasse i-spezifische gene aus dem schwein und deren verwendungen
AP2000001950A0 (en) Paroxetine maleate.
IS4913A (is) Samsetningar sem innihalda VX 478, Zídóvúdín og/eða 1592489 til að nota við meðhöndlunina á HIV
兼正晃 Molecularbiological analysis of picoplankton in lake Biwa and application to the legal medicine.
Berriman The DBS 7
Marchenkov Hegel, Schopenhauer, Hanslick, and Langer on the meaning of music
Nurmesjärvi The concept of form and its change in the music of the Beatles
Wada Part I Discourse of Law and Hidden Power Discourse of Law and Hidden Power
Lee Properties of ORMOSIL with adding organic silane in TEOS system: I

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990322

A4 Supplementary search report drawn up and despatched

Effective date: 19991102

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030301